Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Comparative Evaluation Of Biased Agonists Sarcosine , D-Alanine -Angiotensin (Ang) Ii (Sd Ang Ii) And Sarcosine , Isoleucine -Ang Ii (Si Ang Ii) And Their Radioiodinated Congeners Binding To Rat Liver Membrane At Receptors, Natalia M. Noto, Yazmin M. Restrepo, Hong W. Pang, Filipe Stoyell-Conti, Crystal A. West, Robert C. Speth, Nova Southeastern University
Comparative Evaluation Of Biased Agonists Sarcosine , D-Alanine -Angiotensin (Ang) Ii (Sd Ang Ii) And Sarcosine , Isoleucine -Ang Ii (Si Ang Ii) And Their Radioiodinated Congeners Binding To Rat Liver Membrane At Receptors, Natalia M. Noto, Yazmin M. Restrepo, Hong W. Pang, Filipe Stoyell-Conti, Crystal A. West, Robert C. Speth, Nova Southeastern University
HPD Articles
Angiotensin II analogue and β-arrestin biased agonist TRV027 (Sarcosine , d-Alanine -Angiotensin (Ang) II; SD Ang II), developed by Trevena, Inc. in the early 2010s, brought hopes of a novel treatment for cardiovascular diseases, due to its ability to simultaneously cause signaling through the β-arrestin signaling pathway, while antagonizing the pathophysiological effects of Ang II mediated by the AT receptor G protein signaling cascades. However, a phase II clinical trial of this agent revealed no significant benefit compared to placebo treatment. Using I-Sarcosine , Isoleucine -Ang II ( I-SI Ang II) radioligand receptor competition binding assays, we assessed the relative …